Cargando…

1145. Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 in the US

BACKGROUND: Sotrovimab, a monoclonal antibody (mAb), received Emergency Use Authorization (EUA) for the treatment of high-risk outpatients with symptomatic COVID-19. The study objective was to evaluate real-world effectiveness of sotrovimab (500 mg intravenous) in reducing the risk of mortality or h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Mindy M, Gibbons, Daniel C, Birch, Helen, Patel, Vishal, Bell, Christopher F, Drysdale, Myriam, Satram, Sacha, Reyes, Carolina M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752579/ http://dx.doi.org/10.1093/ofid/ofac492.983

Ejemplares similares

Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA
por: Cheng, Mindy M., et al.
Publicado: (2023)

510. Real-world Effectiveness of Sotrovimab for COVID-19: Evidence from United States (US) Administrative Claims Data
por: Bell, Christopher F, et al.
Publicado: (2023)

CO103 Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the National COVID Cohort Collaborative (N3C)
por: Bell, C., et al.
Publicado: (2023)

512. Interim Results of a Prospective Cohort Study to Monitor the Emergence of Resistance in Immunocompromised Non-Hospitalized Patients With COVID-19 Who Were Treated with Sotrovimab in Great Britain: LUNAR Study 
por: Breuer, Judith, et al.
Publicado: (2023)

Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19
por: Satram, Sacha, et al.
Publicado: (2023)

1145. Sparring With Spores: Ultrasounds as a Vector for Pathogen Transmission in the Intensive Care Unit
por: John, Amrita, et al.
Publicado: (2018)

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
por: Birk, Navina K, et al.
Publicado: (2022)

1145. The Role of Maternal Vaccination on Healthcare Visits for Acute Respiratory Infections in HIV-Exposed but Uninfected (HEU) Infants
por: Kao, Carol M, et al.
Publicado: (2020)

CO56 Real-World Effectiveness of Early Treatments for COVID-19: Evidence from Administrative Claims Data
por: Bell, C., et al.
Publicado: (2023)

1145. The Role of the Plasmid-Mediated Fluoroquinolone-Resistance (PMFQR) Genes As Resistance Mechanisms in Pediatric Infections due to Enterobacterales (Ent)
por: Pitstick, Claire E, et al.
Publicado: (2021)

1145. Meningococcal B Immunization for Adolescents in the Presence of Added Gonorrhea Protection: A Public Health Impact Modelling Study in the United States
por: Kocaata, Zeki, et al.
Publicado: (2023)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

Psycholinguistic dataset on language use in 1145 novels published in English and Dutch
por: Luoto, Severi, et al.
Publicado: (2020)

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
por: Razonable, Raymund R, et al.
Publicado: (2022)

1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab
por: Agostini, Maria L, et al.
Publicado: (2022)

LB1577. Outcomes of Pregnant Women Exposed to Sotrovimab for the Treatment of COVID-19 in the Omicron Predominant Era (PRESTO)
por: Tuan, Jessica, et al.
Publicado: (2022)

1145 2009 H1N1 Compared to Post-pandemic H1N1 Influenza Among Pediatric Inpatients
por: Rao, Suchitra, et al.
Publicado: (2014)

502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
por: Gupta, Anil K, et al.
Publicado: (2021)

Short-term and long-term outcomes of robotic rectal surgery—from the real word data of 1145 consecutive cases in China
por: Chang, Wenju, et al.
Publicado: (2019)

1730. Real-World Use Of Dalbavancin In A US Tertiary Referral Center
por: Bhugra, Mudita, et al.
Publicado: (2022)

Extended Sz Emission Of The Most Luminous X-ray Cluster, Rxj1347-1145
por: Pointecouteau, E
Publicado: (2000)

P1145: OUTCOMES AND TREATMENT PATTERNS AFTER FIRST RELAPSE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
por: Tawfiq, R., et al.
Publicado: (2022)

Prevalence of Fracture Risk Factors in Postmenopausal Women Enrolled in the POSSIBLE US Treatment Cohort
por: Yurgin, Nicole, et al.
Publicado: (2013)

1782. Real-World HIV Diagnostic Testing Patterns in the United States
por: Karichu, James, et al.
Publicado: (2019)

Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
por: Ong, Sean W. X., et al.
Publicado: (2022)

Corrigendum to “Prevalence of Fracture Risk Factors in Postmenopausal Women Enrolled in the POSSIBLE US Treatment Cohort”
por: Yurgin, Nicole, et al.
Publicado: (2017)

497. Safety and tolerability of 2000mg intravenous sotrovimab dose in immunocompromised participants uninfected with SARS-CoV-2 in the PROTECT-V trial
por: Dosanjh, Davinder, et al.
Publicado: (2023)

1145. Reducing Antibiotic Use In Children With Respiratory Syncitial Virus-related Bronchiolitis: Implementation of TeamSTEPPS(®) 2.0 to Improve Pharmacy-Physician Communication in a Community Hospital Antibiotic Stewardship Program
por: Dutta, Ankhi, et al.
Publicado: (2019)

Treatment practice in the elderly patient with chronic lymphocytic leukemia—analysis of the combined SEER and Medicare database
por: Satram-Hoang, Sacha, et al.
Publicado: (2014)

1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year
por: Sension, Michael G, et al.
Publicado: (2022)

518. Comparable Outcomes of Remdesivir and Sotrovimab among High-risk Patients with Mild to Moderate COVID-19 During the Omicron BA.1 Surge
por: Chesdachai, Supavit, et al.
Publicado: (2023)

517. Safety and Tolerability of Intramuscular (IM) Sotrovimab 500 mg Administered at Different Injection Sites: Results from the Phase I COSMIC Study
por: Moore, Jennifer, et al.
Publicado: (2023)

1156. Real-World Effectiveness of Recombinant Zoster Vaccine in Chinese Adults Aged ≥50 Years in the US
por: Florea, Ana, et al.
Publicado: (2023)

Causal inference in multi-state models–sickness absence and work for 1145 participants after work rehabilitation
por: Gran, Jon Michael, et al.
Publicado: (2015)

Sotrovimab: Emergence of acquired resistance: 4 case reports
Publicado: (2022)

2758. Identifying Populations at High-Risk for Influenza-Related Hospitalization: A Real-World Analysis of Commercially Insured Population in the United States
por: Burudpakdee, Chakkarin, et al.
Publicado: (2019)

1154. Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment of Early Mild-to-Moderate COVID-19
por: Gupta, Anil K, et al.
Publicado: (2022)

S107. HEALTHCARE UTILIZATION AND COST IN SCHIZOPHRENIA AND BIPOLAR DISORDER: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
por: Greene, Mallik, et al.
Publicado: (2018)

Economic impact of disease progression in follicular non-Hodgkin lymphoma
por: Beveridge, Roy, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_rm3qgpge4cnslfamhlir9ojuma